Cost-effectiveness of resistance-guided therapy for Mycoplasma genitalium in Australia.
Mycoplasma genitalium
/ drug effects
Humans
Australia
/ epidemiology
Mycoplasma Infections
/ drug therapy
Female
Cost-Benefit Analysis
Male
Anti-Bacterial Agents
/ therapeutic use
Drug Resistance, Bacterial
Azithromycin
/ therapeutic use
Quality-Adjusted Life Years
Adult
Macrolides
/ therapeutic use
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 06 2024
04 06 2024
Historique:
received:
21
01
2024
accepted:
24
05
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
4
6
2024
Statut:
epublish
Résumé
The recommended first-line treatment for Mycoplasma genitalium infections is azithromycin. However, the prevalence of macrolide resistance for M. genitalium has increased to more than 50% worldwide. In 2013, Australia introduced a resistance-guided therapy (RGT) strategy to manage M. genitalium infections. This study assesses the cost-effectiveness of the RGT approach compared to no RGT (i.e., without macrolide resistance profile test) in women, men who have sex with men (MSM), and men who have sex with women (MSW) in Australia. We constructed dynamic transmission models of M. genitalium infections in women, MSM, and MSW in Australia, each with a population of 100,000. These models compared the costs and quality-adjusted life-years (QALYs) gained between RGT and no RGT scenarios from a healthcare perspective over ten years. All costs are reported in 2022 Australian dollars (Australian $). In our model, RGT is cost saving in women and MSM, with the incremental net monetary benefit of $1.3 million and $17.9 million, respectively. In MSW, the RGT approach is not cost-effective, with an incremental cost-effectiveness ratio of -$106.96 per QALY gained. RGT is cost saving compared to no RGT for M. genitalium infections in women and MSM, supporting its adoption as the national management strategy for these two population groups.
Identifiants
pubmed: 38834637
doi: 10.1038/s41598-024-63056-1
pii: 10.1038/s41598-024-63056-1
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azithromycin
83905-01-5
Macrolides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12856Subventions
Organisme : the Australian National Health and Medical Research Council Emerging Leadership Investigator Grant
ID : GNT1193955
Organisme : the Australian National Health and Medical Research Council Emerging Leadership Investigator Grant
ID : GNT1193955
Informations de copyright
© 2024. The Author(s).
Références
Baumann, L. et al. Prevalence of Mycoplasma genitalium in different population groups: Systematic review and meta-analysis. Sex. Transm. Infect 94, 254–261 (2018).
doi: 10.1136/sextrans-2017-053384
Read, T. R. H. et al. Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model. EClinicalMedicine https://doi.org/10.1016/J.ECLINM.2021.100779/ATTACHMENT/1F5B9325-A64E-4904-B53A-4136AB5C1992/MMC1.DOCX (2021).
doi: 10.1016/J.ECLINM.2021.100779/ATTACHMENT/1F5B9325-A64E-4904-B53A-4136AB5C1992/MMC1.DOCX
Oakeshott, P. et al. Is Mycoplasma genitalium in women the ‘new chlamydia?’ A community-based prospective cohort study. Clin. Infect. Dis. 51, 1160–1166 (2010).
doi: 10.1086/656739
pubmed: 20942656
Sonnenberg, P. et al. Epidemiology of Mycoplasma genitalium in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Int. J. Epidemiol. https://doi.org/10.1093/ije/dyv194 (2015).
doi: 10.1093/ije/dyv194
pubmed: 26534946
pmcid: 4690003
Manhart, L. E. et al. Mycoplasma genitalium in the US (MyGeniUS): Surveillance data from sexual health clinics in 4 US regions. Clin. Infect. Dis. 77, 1449–1459 (2023).
doi: 10.1093/cid/ciad405
pubmed: 37402645
pmcid: 10654846
Baumann, L. et al. Prevalence of Mycoplasma genitalium in different population groups: Systematic review and meta-analysis. Sex. Transm. Infect. 94, 255–262 (2018).
doi: 10.1136/sextrans-2017-053384
pubmed: 29440466
Read, T. R. H. et al. Symptoms, Sites, and Significance of Mycoplasma genitalium in Men Who Have Sex with Men. Emerg. Infect. Dis. 25, 719–727 (2019).
doi: 10.3201/eid2504.181258
pubmed: 30882306
pmcid: 6433010
Manhart, L. E., Broad, J. M. & Golden, M. R. Mycoplasma genitalium: Should we treat and how?. Clin Infect Dis 53, S129–S142 (2011).
doi: 10.1093/cid/cir702
pubmed: 22080266
pmcid: 3213402
McGowin, C. L. & Anderson-Smits, C. Mycoplasma genitalium: An emerging cause of sexually transmitted disease in women. PLoS Pathog. 7, e1001324 (2011).
doi: 10.1371/journal.ppat.1001324
pubmed: 21637847
pmcid: 3102684
Lis, R., Rowhani-Rahbar, A. & Manhart, L. E. Mycoplasma genitalium infection and female reproductive tract disease: A meta-analysis. Clin. Infect. Dis. 61, 418–426 (2015).
doi: 10.1093/cid/civ312
pubmed: 25900174
Bissessor, M. et al. The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men. Clin. Microbiol. Infect 22, 260–265 (2016).
doi: 10.1016/j.cmi.2015.11.016
pubmed: 26686807
Ong, J. J. et al. Clinical characteristics of anorectal Mycoplasma genitalium infection and microbial cure in men who have sex with men. Sex. Transm. Dis. 45, 522–526 (2018).
doi: 10.1097/OLQ.0000000000000793
pubmed: 29465653
Jensen, J. S. et al. 2021 European guideline on the management of Mycoplasma genitalium infections. J. Eur. Acad. Dermatol. Venereol. 36, 641–650 (2022).
doi: 10.1111/jdv.17972
pubmed: 35182080
Ong, J. J. et al. Australian sexually transmitted infection (STI) management guidelines for use in primary care 2022 update. Sex Health 20, 1–8 (2023).
doi: 10.1071/SH22134
pubmed: 36356948
Ong, J. J. et al. Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model. EClinicalMedicine 33, 100779. https://doi.org/10.1016/j.eclinm.2021.100779 (2021).
doi: 10.1016/j.eclinm.2021.100779
pubmed: 33842867
pmcid: 8020166
Read, T. R. H. et al. Clinical infectious diseases outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: A prospective evaluation. Clin. Infect. Dis. 68, 554–560 (2019).
doi: 10.1093/cid/ciy477
pubmed: 29873691
Latimer, R. L. et al. The clinical indications for testing women for Mycoplasma genitalium. Sex. Transm. Infect. 98, 277–285 (2022).
pubmed: 34210839
Shilling, H. S. et al. Chlamydia trachomatis and Mycoplasma genitalium prevalence and associated factors among women presenting to a pregnancy termination and contraception clinic, 2009–2019. Sex. Transm. Infect. 98, 115–120 (2022).
doi: 10.1136/sextrans-2020-054695
pubmed: 33782146
Machalek, D. A. et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: A systematic review and meta-analysis. Lancet Infect. Dis. 20, 1302–1314 (2020).
doi: 10.1016/S1473-3099(20)30154-7
pubmed: 32622378
Durukan, D. et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline–2.5 g azithromycin for the treatment of Mycoplasma genitalium infection: Efficacy and tolerability. Clin. Infect. Dis. 71, 1461–1468 (2020).
doi: 10.1093/cid/ciz1031
pubmed: 31629365
Unemo, M. & Jensen, J. S. Antimicrobial-resistant sexually transmitted infections: Gonorrhoea and Mycoplasma genitalium. Nat. Rev. Urol. 14, 139–152 (2017).
doi: 10.1038/nrurol.2016.268
pubmed: 28072403
Walker, J. et al. Mycoplasma genitalium incidence, organism load, and treatment failure in a cohort of young Australian women. Clin. Infect. Dis. 56, 1094–1100 (2013).
doi: 10.1093/cid/cis1210
pubmed: 23300236
Horner, P. J. & Martin, D. H. Mycoplasma genitalium Infection in Men. J. Infect. Dis. 216, S396 (2017).
doi: 10.1093/infdis/jix145
pubmed: 28838074
pmcid: 5853510
Husereau, D. et al. (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. BM Med. 2023, 20 (2022).
Owusu-Edusei, K., Chesson, H. W., Gift, T. L., Brunham, R. C. & Bolan, G. Cost-effectiveness of chlamydia vaccination programs for young women. Emerg. Infect. Dis. 21, 960 (2015).
doi: 10.3201/eid2106.141270
pubmed: 25989525
pmcid: 4451885
Ljubin-Sternak, S. & Meštrović, T. Chlamydia TRACHOMATIS and genital mycoplasmas: Pathogens with an impact on human reproductive health. J. Pathog. 2014, 1–15 (2014).
doi: 10.1155/2014/183167
Ong, J. J. et al. Chlamydia screening for pregnant women aged 16–25 years attending an antenatal service: A cost-effectiveness study. BJOG An. Int. J. Obstet. Gynaecol. 123, 1194–1202 (2016).
doi: 10.1111/1471-0528.13567
Sweeney, E. L., Bradshaw, C. S., Murray, G. L. & Whiley, D. M. Individualised treatment of Mycoplasma genitalium infection-incorporation of fluoroquinolone resistance testing into clinical care. Lancet Infect. Dis. 22, 367–370 (2022).
doi: 10.1016/S1473-3099(21)00629-0
Fernández-Huerta, M., Serra-Pladevall, J., Pich, O. Q., Barberá, M. J. & Espasa, M. From resistance-guided to risk-guided antimicrobial therapy in Mycoplasma genitalium. Sex. Transm. Dis. 47, 409–411 (2020).
doi: 10.1097/OLQ.0000000000001177
pubmed: 32209955
Chua T. Evolving antimicrobial resistance in Mycoplasma genitalium: an updated global systematic review and meta-analysis. 2023.
Vodstrcil, L. A. et al. Combination therapy for Mycoplasma genitalium, and new insights into the utility of parC mutant detection to improve cure. Clin. Infect. Dis. 75, 813–823 (2022).
doi: 10.1093/cid/ciab1058
pubmed: 34984438
Borgogna, J. L. C. et al. The association of Chlamydia trachomatis and Mycoplasma genitalium infection with the vaginal metabolome. Sci. Rep. 10, 3420 (2020).
doi: 10.1038/s41598-020-60179-z
pubmed: 32098988
pmcid: 7042340
Xu, X. et al. Modelling the multiple anatomical site transmission of Mycoplasma genitalium among men who have sex with men in Australia. Sci. Rep. 11, 1–8 (2021).
Doyle, M. et al. Nonquinolone options for the treatment of Mycoplasma genitalium in the era of increased resistance. Open Forum. Infect. Dis. https://doi.org/10.1093/ofid/ofaa291 (2020).
doi: 10.1093/ofid/ofaa291
pubmed: 33575418
pmcid: 7778162
Ong, J. J. et al. Cost-effectiveness of testing for Mycoplasma genitalium among men who have sex with men in Australia. Sex. Transm. Infect. 99(6), 398–403. https://doi.org/10.1136/sextrans-2022-055611 (2023).
doi: 10.1136/sextrans-2022-055611
pubmed: 36958826